Stocks
ACADIA Pharmaceuticals Inc.ACAD
NASDAQHealthcareBiotechnology$20.61-3.10%
Focused on therapies for central nervous system disorders, this biopharmaceutical company develops and commercializes treatments for conditions with limited options, including Parkinson’s disease psychosis and Rett syndrome. Revenue is driven primarily by Nuplazid, with newer products such as Daybue...
Market Cap: $3.5B52W Range: $13.40 – $28.35
Congressional Interest in ACADIA Pharmaceuticals Inc. (ACAD)
3 members of Congress have disclosed 4 trades in ACADIA Pharmaceuticals Inc. (ACAD), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
3
Buys
1
Sells
3
Who in Congress Is Trading ACAD?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-06-16 | Christopher L. Jacobs | sell | $1K – $15K |
| 2020-09-08 | Christopher L. Jacobs | sell | $1K – $15K |